BIA
BLFS icon

Bell Investment Advisors’s BioLife Solutions BLFS Stock Holding History

Bell Investment Advisors’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21
Closed – – 1943
2022
Q3 		$0 Buy
+21
New +$449 ﹤0.01% 1732
2021
Q4 		$0 Buy
+12
New +$515 ﹤0.01% 1783

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Bell Investment Advisors's BLFS Position: Q4 2022 in Review

Bell Investment Advisors sold out of BioLife Solutions (BLFS) in Q4 2022, closing a stake of 21 shares.

Bell Investment Advisors first reported a position in BLFS in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 165 funds tracked by Wall St. Rank hold BLFS as of Q4 2022.

  • Bell Investment Advisors reported no remaining BioLife Solutions position as of Q4 2022 after selling out during the quarter.
  • Bell Investment Advisors sold 21 BioLife Solutions shares in Q4 2022.
  • Bell Investment Advisors first reported a position in BioLife Solutions in Q4 2021 and held it in 2 quarters.
  • Bell Investment Advisors's BioLife Solutions position peaked at $0 in Q3 2022.
  • 165 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2022.

Based on Bell Investment Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.